Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Rasagiline mesylate, a new MAO-B inhibitor for the treatment of Parkinson's disease: A double-blind study as adjunctive therapy to levodopa
Autore:
Rabey, JM; Sagi, I; Huberman, M; Melamed, E; Korczyn, A; Giladi, N; Inzelberg, R; Djaldetti, R; Klein, C; Berecz, G;
Indirizzi:
Assaf Harofeh Med Ctr, Dept Neurol, IL-70300 Zerifin, Israel Assaf HarofehMed Ctr Zerifin Israel IL-70300 , IL-70300 Zerifin, Israel Tel Aviv Univ, Sackler Fac Med, IL-69978 Tel Aviv, Israel Tel Aviv Univ Tel Aviv Israel IL-69978 ac Med, IL-69978 Tel Aviv, Israel
Titolo Testata:
CLINICAL NEUROPHARMACOLOGY
fascicolo: 6, volume: 23, anno: 2000,
pagine: 324 - 330
SICI:
0362-5664(200011/12)23:6<324:RMANMI>2.0.ZU;2-7
Fonte:
ISI
Lingua:
ENG
Soggetto:
MONOAMINE-OXIDASE-B; RAT;
Keywords:
MAO-B inhibiting rasagiline; Parkinson's disease; motor fluctuations;
Tipo documento:
Review
Natura:
Periodico
Settore Disciplinare:
Life Sciences
Citazioni:
15
Recensione:
Indirizzi per estratti:
Indirizzo: Rabey, JM Assaf Harofeh Med Ctr, Dept Neurol, IL-70300 Zerifin, Israel Assaf Harofeh Med Ctr Zerifin Israel IL-70300 Zerifin, Israel
Citazione:
J.M. Rabey et al., "Rasagiline mesylate, a new MAO-B inhibitor for the treatment of Parkinson's disease: A double-blind study as adjunctive therapy to levodopa", CLIN NEUROP, 23(6), 2000, pp. 324-330

Abstract

Rasagiline mesylate (TVP-1012) is a potent, selective, non-reversible MAO-B inhibitor, without the tyramine-potentiating effect and with neuroprotective activities. The benefit of rasagiline as monotherapy in patients with early Parkinson's disease (PD) has already been reported. To evaluate the safety, tolerability, and clinical effect of rasagiline as adjunctive therapyto levodopa, a multicenter, double-blind, randomized, placebo-controlled, parallel-group study (0.5, 1, and 2 mg/d) was conducted for 12 weeks in 70 patients with PD (mean age, 57.4 y; mean disease duration, 5.7 y; 32 patients had motor fluctuations). A beneficial clinical effect was observed in fluctuating patients treated with rasagiline (all doses), expressed as a decrease in total Unified Parkinson's Disease Rating Scale (UPDRS) score (23.0%vs 8.5% in the placebo group). The treatment effect was still evident 6 weeks after drug discontinuation (in all doses). The safety and tolerability of rasagiline were good. Adverse events were no different than those of patients taking placebo. Almost complete platelet MAO-B inhibition was obtained at all rasagiline doses. This study has demonstrated that rasagiline (up to 2 mg/day) has a good safety profile and a beneficial clinical effect in fluctuating patients with PD when given as an add-on to chronic levodopa therapy.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 22/10/20 alle ore 00:05:26